Neurodegenerative, autoimmune and genetic processes of human and animal narcolepsy;Aspects neurodégénératifs, autoimmunes et génétiques de la narcolepsie humaine et animale

Revue Neurologique

Volumn 159, Issue 11 SUPPL., 2003, Pages

  Dauvilliers, Y ^a,b  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b Montpellier 1 University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA DQB1 ANTIGEN; OREXIN; OREXIN ANTAGONIST; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CATAPLEXY; CELL LOSS; CLINICAL FEATURE; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; GENETICS; HUMAN; INSOMNIA; MONOAMINERGIC SYSTEM; NARCOLEPSY; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE;

ANIMALS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; CATAPLEXY; CELL DEATH; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ ANTIGENS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NARCOLEPSY; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345307222     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. e édition. Masson, Paris, 278-292.
2. BILLIARD M, PASQUIE-MAGNETTO V, HECKMAN M, et al. (1994). Family studies in narcolepsy. Sleep, 17: S54-S59.
3. CARLANDER B, ELIAOU JF, BILLIARD M. (1993). Autoimmune hypothesis in narcolepsy. Neurophysiol Clin, 23: 15-22.
4. CHEMELLI RM, WILLIE JT, SINTON C. M, et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 98: 437-451.
5. DAUVILLIERS Y, MONTPLAISIR J, MOLINARI N, CARLANOER B, ONDZE B, BESSET A, BILLIARD M. (2001). Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology, 57: 2029-2033.
6. DAUVILLIERS Y, NEIDHART E, LECENOREUX M, BILLIARD M, TAFTI M. (2001). MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry, 6: 367-372.
7. DAUVILLIERS Y, NEIDHART E, BILLIARD M, TAFTI M. (2002). Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. Pharmacogenomics J, 2: 65-68.
8. ELIAS CF, LEE CE, KELLY JF, et al. (2001). Characterization of CART neurons in the rat and human hypothalamus. J Comp Neurol, 432: 1-19.
9. FEHR C, SCHLEICHER A, SZEGEDI A, ANGHELESCU I, KLAWE C, HIEMKE C, DAHMEN N. (2001). Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. Prog Neuropsychopharmacol Biol Psychiatry, 25: 965-82.
10. GENCIK M, DAHMEN N, WIECZOREK S, KASTEN M, GENCIKOVA A, EPPLEN JT. (2001). ApoE polymorphisms in narcolepsy. BMC Med Genet, 2: 9.
11. GENCIK M, DAHMEN N, WIECZOREK S, et al. (2001). A prepro-orexin gene polymorphism is associated with narcolepsy. Neurology, 56: 115-117.
12. HARA J, BEUCKMANN CT, NAMBU T, et al. (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron, 30: 345-354.
13. HOHJOH H, NAKAYAMA T, OHASHI J, et al. (1999). Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy. Tissue Antigens, 54: 138-145.
14. HOHJOH H, TERADA N, KAWASHIMA M, HONDA Y, TOKUNAGA K. (2000). Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens, 56: 446-448.
15. HUNGS M, LIN L, OKUN M, MIGNOT E. (2001). Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology, 57: 1893-1895.
16. ICSD. International classification of sleep disorders (1990). Diagnostic and coding manual Rochester, Minnesota: American Sleep Disorders Association.
17. JOHN J, WU MF, SIEGEL JM. (2000). Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online, 3: 23-8.
18. KANBAYASHI T, NISHINO S, TAFTI M, HISHIKAWA Y, DEMENT WC, MIGNOT E. (1996). Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. Neuroreport, 12: 1881-6.
19. KANBAYASHI T, INOUE Y, CHIBA S, et al. (2002). CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res, 11: 91-3.
20. KILDUFF T, RADDE L, BURTCH L, STEINMAN L, DEMENT WC. (1987). Immuno-suppression with cyclosporine as a treatment for canine narcolepsy. Sleep Res, 16: 369.
21. KOCH H, CRAIG I, DAHLITZ M, DENNEY R, PARKES D. (1999). Analysis of the monoamine oxidase genes and the Norrie disease gene locus in narcolepsy. Lancet, 353: 645-646.
22. LIN L, FARACO J, LI R, et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98: 365-376.
23. MIGNOT E, TAFTI M, DEMENT WC, GRUMET FC. (1995). Narcolepsy and immunity. Adv Neuroimmunol, 5: 23-37.
24. IMIGNOT E. (1998). Genetic and familial aspects of narcolepsy. Neurology, 50 (suppl 1): S16-S22.
25. MIGNOT E, LIN L, ROGERS W, et al. (2000). Complex HLA-DR and - DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet, 68: 686-699.
26. MIGNOT E, LAMMERS GJ, RIPLEY B, et al. (2002). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol, 59: 1553-1562.
27. NAKAYAMA J, MIURA M, HONDA M, MIKI T, HONDA Y, ARINAMI T. (2000). Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics, 65: 84-6.
28. NISHINO S, MIGNOT E. (1997). Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol, 52: 27-78.
29. PEYRON C, FARACO J, ROGERS W, et al. (2000). A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med, 6: 991-997.
30. POLITO JM 2nd, CHILDS B, MELLITS ED, TOKAYER AZ, HARRIS ML, BAYLESS TM. (1996). Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology, 111: 580-586.
31. RIPLEY B, OVEREEM S, FUJIKI N, et al. (2001). CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology, 57: 2253-2258.
32. RIPLEY B, FUJIKI N, OKURA M, MIGNOT E, NISHINO S. (2001). Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis, 8: 525-534.
33. SIEGEL JM, NIENHUIS R, GULYANI S, et al. (1999). Neuronal degeneration in canine narcolepsy. J Neurosci, 19: 248-257.
34. TAFTI M, NISHINO S, ALDRICH MS, LIAO W, DEMENT WC, MIGNOT E. (1996). Major histocompatibility class II molecules in the CNS: increased microglial expression at theonset of narcolepsy in canine model. J Neurosci, 16: 4588-4595.
35. THANNICKAL TC, MOORE RY, NIENHUIS R, et al. (2000). Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27: 469-474.
36. VGONTZAS AN, PAPANICOLAOU DA, BIXLER EO, KALES A, TYSON K, CHROUSOS GP. (1997). Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab, 82: 1313-1316.